Accelrys Revenues Down in First Quarter as Standalone Company, Two New Execs Hired | GenomeWeb

In its first quarter since separating from Pharmacopeia, Accelrys reported an expected downturn in revenues, but indicated it is growing roots as an independent software firm, with the hires of two new executives, and the launch of a nanotechnology software consortium.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.